In the News

Share

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
COVID-19: Information for Patients and Caregivers

We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.

What you need to know

459 News Items found
In the Clinic
Illustration of breast cancer cell
Targeted Drug Shows Promise Against HER2-Positive Breast Cancer That Stops Responding to Other Drugs

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.
Rachel Samuels Rand (l) with her husband, Brendan Rand.
3-D Nipple Tattoos After Breast Cancer Surgery: An MSK Specialty

Learn how specialists at Memorial Sloan Kettering tattoo highly realistic nipples and areolas on people who have had them removed during surgery for breast cancer.
Memorial Sloan Kettering Ralph Lauren Center nurse Jasmine Gibson, breast cancer patient Maria Tucker, and nurse Margaret Bediones
Expert Breast Cancer Treatment in Harlem at MSK’s Ralph Lauren Center

See how experts at Memorial Sloan Kettering Cancer Center's Ralph Lauren Center cared for Maria close to home.
In the Clinic
Shanu Modi
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Finding
Radiologist Maxine Jochelson
Imaging and Artificial Intelligence Tools Help Predict Response to Breast Cancer Therapy

For HER2-positive breast cancers, MRI scans that employ machine-learning algorithms can provide more guidance than biopsies alone.
In the Lab
Image of dividing breast cancer cells taken with electron microscope.
Researchers Identify Why Women May Develop Resistance to a New Class of Breast Cancer Drugs

Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.
Boris Mueller, MD, Director, Radiation Oncology at MSK Bergen is seen standing in a hallway.
Breast Cancer and Tattoo-Less Radiation at MSK

Learn how people with early stage breast cancer can receive radiation therapy without the need for tattoos at Memorial Sloan Kettering Cancer Center.
In the News
Man meets with a doctor
FDA Recommends Including Men in Breast Cancer Trials

The recommendation comes in the form of draft guidelines open for public comment until October 2019.
Finding
Kate Delp standing on the beach, smiling and holding a yoga mat
Why More People With Breast Cancer Are Choosing Lumpectomy Over Mastectomy: Kate’s Story

An MSK study found a rise in lumpectomies and a decline in mastectomies — reversing a trend that experts say was leading to the overtreatment of breast cancer.
In the Clinic
Two female healthcare professionals performing a mammogram on a patient
For Less Familiar Gene Mutations Linked to Breast Cancer, Research Aims to Create Screening Guidelines

Computer models suggest breast cancer screening guidelines for people with mutations in the genes ATM, CHEK2, and PALB2.